Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report

Background: HER 2 Metastatic Breast Cancer (MBC) is usually considered incurable. Prognosis has considerably improved over the past two decades with the advent of new therapies such as monoclonal antibodies interfering with the Her2/neu receptor. Case presentation: We present a case of 61 year old woman with Her2 positive MBC without any sign of recurrence 5 years after the end of trastuzumab and who could be potentially considered cured. Conclusion: In case of sustained response, stopping trastuzumab is possible without recurrence. We can reasonably hope that patients without recurrence after 5 years, as in our case, are definitely cured.